Cardiovascular Pharmacotherapeutics, Vol. 2

Author: WIlliam H. Frishman
Published: May 2003
Publisher: McGraw-Hill Professional
ISBN: 0071426515
Hardcover Book
Number of Pages: 592

Click to compare book prices for Cardiovascular Pharmacotherapeutics, Vol. 2

This is the second book in a two-volume set. The definitive guide for practicing physicians and pharmacists who need to know about drug therapy for heart conditions. The fully updated Second Edition explores mechanisms of action, all the cardiovascular agents now available, drugs in development, molecular biological advances, and specific drug treatments. Frishman, William H., MD (Albert Einstein Coll of Medicine); Sonnenblick, Edmund H., MD (Albert Einstein Coll of Medicine)The contributors represent the specialties of cardiology, general medicine, pharmacology, nephrology, and pulmonary medicine. Most are from U.S. universities and academic medical centers, with one each from the U.K. and South Africa. Institutions prominently represented include Albert Einstein Coll of Medicine, Mount Sinai School of Medicine, Cornell, Boston Univ, and Columbia.

Table of Contents
Contributors
Foreword
Preface
Pt. I Introductory Chapters 1
1 Basic Principles of Clinical Pharmacology Relevant to Cardiology 3
2 The Placebo Effect in Cardiovascular Disease 15
3 Compliance with Cardiovascular Drug Treatment 27
4 New Drug Development and FDA Approval 35
5 Health Economic Considerations in Cardiovascular Drug Utilization 43
6 Cardiovascular Pharmacology: A Historical Perspective 57
Pt. II Drug Classes 65
7 Alpha- and Beta-Adrenergic Blocking Drugs 67
8 Cholinergic and Anticholinergic Drugs 99
9 Calcium Channel Blockers 105
10 The Renin-Angiotensin Axis: Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers 131
11 Diuretic Therapy in Cardiovascular Disease 157
12 Magnesium, Potassium, and Calcium as Potential Cardiovascular Disease Therapies 177
13 Inotropic Agents 191
14 The Organic Nitrates and Nitroprusside 203
15 Antiadrenergic Drugs with Central Action and Neuron Depletors 215
16 Nonspecific Antihypertensive Vasodilators 221
17 Antiarrhythmic Drugs 225
18 Antiplatelet and Antithrombotic Drugs 259
19 Thrombolytic Agents 301
20 Lipid-Lowering Drugs 317
21 Combination Drug Therapy 355
22 Tobacco Smoking, Nicotine, and Nicotine and Non-Nicotine Smoking Cessation Therapies 369
23 Fish Oils, the B Vitamins, and Folic Acid as Cardiovascular Protective Agents 381
24 Antioxidant Vitamins and Enzymatic and Synthetic Oxygen-Derived Free-Radical Scavengers in the Prevention and Treatment of Cardiovascular Disease 407
25 Use of Prostacyclin and Its Analogues in the Treatment of Pulmonary Hypertension and Other Cardiovascular Diseases 429
26 Selective and Nonselective Dopamine-Receptor Agonists 443
27 Natriuretic and Other Vasoactive Peptides 451
Pt. III New Drug Classes in Development 479
28 Potassium-Channel Openers and Sodium/Hydrogen-Channel Effectors 481
29 Serotonin and Its Antagonists in Cardiovascular Disease 501
30 Imidazoline-Receptor Agonist Drugs for the Treatment of Systemic Hypertension and Congestive Heart Failure 515
31 Endothelin as a Therapeutic Target in the Treatment of Cardiovascular Disease 527
32 Adenosine-Receptor Agonism and Antagonism in Cardiovascular Disease 545
33 Nitric Oxide Donor Drugs in the Treatment of Cardiovascular Diseases 565
34 Specific Inhibitors of Renin in Cardiac Therapy 589
35 Vasopressin and Vasopressin-Receptor Antagonists in the Treatment of Cardiovascular Disease 601
36 Hormones as Cardiovascular Drugs: Estrogens, Progestins, Thyroxine, Growth Hormone, Corticosteroids, and Testosterone 617
37 Innovative Pharmacologic Approaches to the Treatment of Myocardial Ischemia
38 Therapeutic Angiogenesis: A New Treatment Modality for Ischemic Heart Disease 691
39 Innovative Drug Targets for Treating Cardiovascular Disease: Adhesion Molecules, Cytokines, Neuropeptide Y, Calcineurin, Bradykinin, Urotensin, and Heat Shock Protein
40 Pharmacologic Therapies for the Prevention of Restenosis Following Percutaneous Coronary Artery Interventions 741
41 Gene Transfer in the Cardiovascular System 777
42 Inhibition of Myocardial Apoptosis as a Therapeutic Target: Focus on Caspase Inhibition 789
43 Matrix Metalloproteinases and Their Inhibitors in Cardiovasular Disease 797
44 Vasopeptidase Inhibitors: Neutral Endopeptidase Inhibitors and Dual Inhibitors of Anglotensin-Converting Enzyme and Neutral Endopeptidase 813
45 The Many Faces of Eicosanoids: Prostaglandins, Leukotrienes, and Other Arachidonate Metabolites 821
46 Innovative Medical Approaches for the Treatment of Hyperlipidemia 841
Pt. IV Special Topics 855
47 Use of Alternative/Complementary Medicine in Treating Cardiovascular Disease 857
48 Cardiovascular Drug Interactions 875
49 Pediatric Cardiovascular Pharmacology 893
50 Drug Treatment of Peripheral Vascular Disease 919
51 Quality-of-Life Issues with Cardiovascular Drug Therapy 935
Pt. V Appendices 943
App. 1 Pharmacokinetic Properties of Approved Cardiovascular Drugs 945
App. 2 Therapeutic Use of Available Cardiovascular Drugs 961
App. 3 Guide to Cardiovascular Drugs Use in Pregnancy and with Nursing 1015
App. 4 Dosing Recommendations of Cardiovascular Drugs in Patients with Hepatic Disease and/or Congestive Heart Failure 1021
App. 5 Dose Adjustment in Patients with Renal Insufficiency 1025
App. 6 Selected Cardiovascular Medications and Gender Issues 1031
App. 7 Pharmacokinetic Changes, Route of Elimination, and Dosage Adjustment of Selected Cardiovascular Drugs in the Elderly 1033
App. 8 Selected Cardiovascular Medications and Ethnic Issues 1037
Index 1039

Click to compare book prices for Cardiovascular Pharmacotherapeutics, Vol. 2 Cardiovascular Pharmacotherapeutics, Vol. 2

Compare Shop Books - Help - About - Book Links - Book Coupons